Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesBiodexa Pharmaceticals

Biodexa Pharmaceticals

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
2.4999 USD 0.02 ( 0.82%)
Last update at 2026-11-09T15:30:00Z
VOLUME
3103
Market Cap
2.59M

Momentum Score

…

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
2.38
Low
2.56
High
52 Week Price Range
2.86
Low
96.50
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public information on Biodexa Pharmaceuticals (BDRX) is limited; filings and company descriptions indicate it is a biopharmaceutical developer focused on advancing therapeutic candidates through clinical stages. Long-term growth may be driven by successful clinical trials, regulatory approvals and licensing or commercialization partnerships, so investors may find exposure to meaningful upside if programs progress.
Key risks include high probability of clinical or regulatory failure, significant financing and dilution needs with likely low trading liquidity, and operational execution risk typical of early-stage drug developers.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
2.48
Dividend Yield
-
Revenue TTM
0.08M
Revenue Per Share
0.43
Gross Profit TTM
-3.96M
Debt / Equity
0.01
ROE
-64.72%
Net Debt
-8.46M
ROCE
-68.74%
Diluted EPS TTM
-3.37

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -6.35M -5.98M -7.49M -8.49M -6.11M
Net income -6.24M -5.73M -7.08M -7.66M -5.46M
Selling general administrative 4.84M 3.79M 4.34M 4.54M 2.95M
Gross profit -0.18M -5.44M -3.69M -4.41M -4.08M
Reconciled depreciation 0.19M 0.25M 0.28M 0.34M 0.40M
Ebit -8.27M -9.20M -7.44M -8.93M -7.00M
Ebitda -8.08M -9.08M -7.16M -8.76M -6.79M
Depreciation and amortization 0.18M 0.12M 0.28M 0.18M 0.21M
Operating income -8.27M -9.20M -8.01M -8.93M -7.00M
Other operating expenses 8.27M 9.20M 8.39M 9.16M 6.64M
Interest expense 0.07M 0.17M 0.04M 0.05M 0.04M
Tax provision -0.10M -0.25M -0.41M -0.83M -0.65M
Interest income 0.09M 0.17M 0.08M 0.03M 0.00M
Net interest income -0.14M 0.00M 0.04M -0.02M -0.04M
Income tax expense -0.10M -0.25M -0.41M 0.83M 0.65M
Total revenue 0.00M 0.00M 0.38M 0.70M 0.58M
Total operating expenses 8.08M 3.76M 4.33M 4.05M 1.99M
Cost of revenue 0.18M 5.44M 4.07M 5.11M 4.65M
Total other income expense net 1.92M 3.22M 0.53M 0.44M 0.89M
Net income from continuing ops -6.38M -5.73M -7.08M -7.66M -5.46M
Net income applicable to common shares - - - - -5.46M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 18.15M 14.78M 10.54M 5.53M 12.91M
Intangible assets 5.64M 5.65M 2.94M 0.01M -
Other current assets 3.68M 6.43M 1.06M - -
Total liab 6.76M 6.46M 5.86M 2.36M 2.46M
Total stockholder equity 11.38M 8.32M 4.68M 3.16M 10.45M
Other current liab 5.49M 2.20M 4.16M 0.10M 0.60M
Common stock 14.07M 6.69M 1.19M 1.11M 0.10M
Capital stock 14.10M 6.69M 1.19M 1.11M 0.10M
Retained earnings -102.62M -150.42M -144.77M -135.34M -127.80M
Good will 0.00M 0.00M 0.00M 0.00M 0.00M
Cash 8.52M 1.67M 5.97M 2.84M 10.06M
Total current liabilities 6.12M 5.03M 5.57M 1.90M 1.84M
Current deferred revenue 0.57M 1.47M 0.93M 0.20M -
Net debt -8.46M -0.94M -5.51M -2.21M -9.29M
Short term debt 0.06M 0.61M 0.17M 0.16M 0.15M
Short long term debt - - - 0.00M 0.00M
Short long term debt total 0.06M 0.73M 0.46M 0.62M 0.77M
Other stockholder equity 98.75M 99.06M 95.25M 84.39M 138.16M
Property plant equipment - - - - 1.15M
Total current assets 12.42M 8.81M 7.03M 4.69M 11.76M
Net tangible assets - - - - 10.45M
Net receivables 0.22M 0.71M 0.70M 1.48M 1.70M
Long term debt - - - - 0.00M
Inventory - - -0.70M - -
Accounts payable 0.10M 0.71M 0.31M 1.45M 1.09M
Accumulated other comprehensive income 1.19M 53.00M 53.00M 53.00M -
Non current assets total 5.73M 5.97M 3.51M 0.84M 1.15M
Capital lease obligations 0.06M 0.73M 0.46M 0.62M 0.77M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.60M -0.27M -0.22M -0.28M
Change to liabilities - - - - -0.13M
Total cashflows from investing activities -0.66M -0.60M -0.27M - -0.28M
Net borrowings -0.70M 0.24M -0.19M - -0.21M
Total cash from financing activities 12.77M 8.56M 10.23M 0.05M 8.80M
Net income -6.24M -5.73M -7.08M -7.66M -5.46M
Change in cash 6.97M -4.30M 3.13M -7.22M 2.51M
Begin period cash flow 1.55M 5.97M 2.84M 10.06M 7.55M
End period cash flow 8.52M 1.67M 5.97M 2.84M 10.06M
Total cash from operating activities -5.39M -12.26M -6.83M -7.05M -6.01M
Issuance of capital stock 13.75M 8.31M 10.43M 0.24M 9.04M
Depreciation 0.18M 0.25M 0.28M 0.34M 0.40M
Other cashflows from investing activities - -0.59M -0.24M - -
Dividends paid 0.00M 0.00M 0.00M 0.00M -
Change to account receivables 2.57M -5.97M 0.36M - -0.49M
Other cashflows from financing activities -0.24M - -0.01M -0.02M -0.13M
Change to netincome - - - - -0.33M
Capital expenditures 0.00M 0.77M 0.26M 0.06M 0.32M
Change in working capital 1.68M -3.74M -0.05M 0.52M -0.62M
Stock based compensation 0.17M 0.28M 0.03M 0.12M 0.09M
Other non cash items -1.01M -3.08M 0.40M 0.45M -0.42M
Free cash flow -5.40M -13.04M -7.09M -7.11M -6.33M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
BDRX
Biodexa Pharmaceticals		 0.02
0.82%		 2.50 - - 0.58 0.18 4.70 0.03
NVO
Novo Nordisk A/S		 0.47
1.18%		 40.78 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 0.34
0.06%		 547.43 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 8.76
0.97%		 913.11 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Biodexa Pharmaceticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

1 Caspian Point, Cardiff, United Kingdom, CF10 4DQ

44 29 2048 0180

https://www.biodexapharma.com

11

Name Title Year Born
Mr. Stephen A. Stamp CEO, CFO, Company Secretary & Director 1962
Dr. Dmitry Zamoryakhin M.D. Chief Scientific Officer & Chief Medical Officer 1980
Dr. Daniel Palmer MBA, Ph.D. Vice President of Technology NA
Ms. Nicola Tuckwell VP & Head of Clinical Operations NA
Ms. Fiona Sharp Group Financial Controller NA
Mr. Steve Ellul Chief Business Officer NA
Mr. Stephen Anthony Stamp CEO, CFO, Company Secretary & Director 1961
Dr. Gary A. Shangold CPI, FACOG, M.D. Chief Medical Officer 1954
Mr. Stephen Anthony Stamp CEO & Director 1961
Ms. Fiona Mary Powell Company Secretary, CFO & Director 1968

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…